View on Pubmed.gov 31527695 | View on doi.org 10.1038/s41598-...
Comprehensive proteomic profiling of plasma-derived Extracellular Vesicles from dementia with Lewy Bodies patients.
- Department of Pathology, Hospital Universitari and Health Sciences Research Institute Germans Trias i Pujol, Universitat Autònoma de Barcelona, Badalona, Barcelona, Spain.
- REMAR-IVECAT group, Health Sciences Research Institute Germans Trias i Pujol, Badalona, Barcelona, Spain.
- Department of Neurology, Hospital Universitari de Bellvitge, L'Hospitalet de Llobregat, Barcelona, Spain.
- Department of Pathology, Hospital Universitari and Health Sciences Research Institute Germans Trias i Pujol, Universitat Autònoma de Barcelona, Badalona, Barcelona, Spain. katrinbeyer@hotmail.com.
- REMAR-IVECAT group, Health Sciences Research Institute Germans Trias i Pujol, Badalona, Barcelona, Spain. feborras@igtp.cat.
- Nephrology Service, Hospital Universitari Germans Trias i Pujol, Badalona, Barcelona, Spain. feborras@igtp.cat.
- Department of Cell Biology, Physiology and Immunology, Universitat Autònoma de Barcelona (UAB), Barcelona, Spain. feborras@igtp.cat.
Abstract
Proteins and nucleic acids contained in extracellular vesicles (EVs) are considered a feasible source of putative biomarkers for physiological and pathological conditions. Within the nervous system, not only neurons but also other brain cells are able to produce EVs, which have been involved in their physiological processes and also in the development and course of several neurodegenerative diseases. Among these, dementia with Lewy bodies (DLB) is the second cause of dementia worldwide, though most cases are missed or misdiagnosed as Alzheimer's disease (AD) due to the important clinical and pathological overlap between both diseases. In an attempt to find reliable biomarkers for DLB diagnosis, our group characterized the proteome of plasma-derived EVs from DLB patients compared to aged-matched healthy controls (HCs) using two different proteomic LC-MS/MS approaches. Remarkably, we found that gelsolin and butyrylcholinesterase were differentially identified between DLB and HCs. Further validation of these results using conventional ELISA techniques, and including an additional group of AD patients, pointed to decreased levels of gelsolin in plasma-EVs from DLB compared to HCs and to AD samples. Thus, gelsolin may be considered a possible biomarker for the differentiation between DLB and AD.
References
Proteomics. 2015 Aug;15(15):2597-601
Nucleic Acids Res. 2017 Jan 4;45(D1):D183-D189
J Extracell Vesicles. 2014 Sep 08;3:
Crit Rev Biochem Mol Biol. 2012 May-Jun;47(3):282-96
Cited by 24 citations (total)
Journal Article Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, P.H.S.
Alzheimer's disease progression characterized by alterations in the molecular profiles and biogenesis of brain extracellular vesicles.
Electronic publication date June 25, 2021
Xavier Gallart-Palau [...] Siu Kwan Sze et al.
BACKGROUND
The contributions of brain intercellular communication mechanisms, specifically extracellular vesicles (EV), to the progression of Alzheimer's disease (AD) remain poorly...
Journal Article
Linking Parkinson's disease and melanoma: the impact of copper-driven cuproptosis and related mechanisms.
Electronic publication date April 13, 2025
Quan Wang [...] Yi Yang et al.
Patients with Parkinson's disease (PD) exhibit an increased risk of melanoma, implying shared yet incompletely understood molecular mechanisms. This study...
Conflict of interest statement
MeSH
- •
- •
- •
- •
- •
Specialties
- •
- •
- •
- •
- •
- •
- •
- •
- •
- •
Substances
- •
- •
- •